Delta-Beta-Thalassemia is a recessive genetic disorder of globin synthesis. Defective synthesis leads to insufficient amounts of both delta and beta chains of hemoglobin in red blood cells (hence the name of the condition), and consequently to anemia.

The manifestations of thalassemias are variable: in addition to the nature of the genetic alterations and the homozygous or heterozygous state of the patient, the severity of the disease is also influenced by supplementary factors [1]. For example, DBT is a relatively benign condition, because it is associated with increased synthesis of fetal hemoglobin (HbF) [2]. Thus, heterozygous patients have symptoms that resemble the mild manifestations of the beta thalassemia trait or may be essentially asymptomatic. Similarly, homozygotes show a clinical severity similar to thalassemia intermedia, instead of the debilitating features of thalassemia major (Cooley’s anemia) displayed by homozygotes for beta chain deficiency only.

DBT is often caused by deletions of the adjacent beta and delta genes within the beta globin cluster on chromosome 11p15. The deletion may include regulatory elements for the fetal gamma globin genes, or change the structure or the distance of such elements from the gamma genes, allowing the expression of gamma chains during adult life [3]. Another condition in which HbF expression continues into adult life is a classic hereditary persistence of fetal hemoglobin (HPFH), some forms of which are caused by deletions within the beta globin cluster, others by mutations in the gamma globin genes. Neither homozygotes nor heterozygotes with HPFH tend to exhibit symptoms. HPFH is the main disease from which DBT has to be differentiated; however, not all cases of the two conditions can be unambiguously distinguished [3].

The cases homozygous for DBT display signs of moderate anemia. Patients (usually young) may appear pale and weak and present with jaundice [4] [5], and with hepatosplenomegaly [6].

DBT, especially the homozygous form – is rare. However, this condition, as well as HPFH, is relatively frequent in Thailand [7]. The characteristics of DBT are also observed in people suffering from Gamma-Delta-Beta-Thalassemia and in more complex inversion-deletion-type Gamma-Delta-Beta-thalassemia [1].

A physical evaluation may show palpable liver or spleen, while the history may reveal consanguineous marriage of parents or other relevant findings. Hematologic examination is crucial (such as complete blood count, and peripheral smear), and will reveal hypochromic microcytic anemia. Other signs of anemia may be the presence of reticulocytes, nucleated red blood cells, and target cells [6]. Increased total and indirect bilirubin levels provide further evidence for hemolytic anemia [6]. An important method to differentiate Delta-Beta-Thalassemia from HPFH is the Kleihauer-Betke test [4], which can be used to visualize the distribution of fetal hemoglobin in red blood cells. HbF is unevenly distributed in the red cells of heterozygous DBT patients (heterocellular distribution), while red cells in heterozygotes of HPFH show pancellular distribution of HbF [4] [6].

Hemoglobins can be quantitated by electrophoresis, chromatography or high-performance liquid chromatography (HPLC). HbF is the only hemoglobin present in homozygotes of DBT, whereas heterozygotes have 5-20% of their hemoglobin composed of HbF [4] – somewhat lower than the HbF percentage in heterozygotes of HPFH. Heterozygotes of Delta-Beta-Thalassemia also have normal levels of HbA2 (the delta chain-containing hemoglobin), as opposed to those suffering from beta-thalassemia, who have increased HbA2 levels.

Analysis of the beta globin locus can confirm the diagnosis. Various molecular methods, among which the polymerase chain reaction (PCR) is prominent, can be used to determine the nature of mutations or delineate the extent of deletions. PCR methods have the power to distinguish among variants of the deletional thalassemias, including complex cases that involve inversion-deletions [1] [7].

Treatment for HPFH - Beta Thalassemia is generally supportive and focuses on managing symptoms. Patients with mild anemia may not require treatment, while those with more significant symptoms might benefit from folic acid supplements or occasional blood transfusions. Regular monitoring by a healthcare provider is essential to manage any complications that may arise.

The prognosis for individuals with HPFH - Beta Thalassemia is generally favorable. The presence of fetal hemoglobin often reduces the severity of symptoms associated with beta thalassemia. Most patients experience a mild form of anemia and can maintain a good quality of life with minimal intervention. Lifespan is typically normal, and severe complications are rare.

HPFH - Beta Thalassemia is caused by genetic mutations that affect hemoglobin production. The condition results from a combination of mutations that lead to the persistence of fetal hemoglobin and those that cause beta thalassemia. These mutations are inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the mutated gene for a child to be affected.

HPFH - Beta Thalassemia is relatively rare and occurs more frequently in certain populations, including those of African, Mediterranean, and Southeast Asian descent. The prevalence varies widely depending on the geographic region and the specific genetic mutations involved.

In HPFH - Beta Thalassemia, the genetic mutations lead to the continued production of fetal hemoglobin, which can compensate for the reduced production of adult hemoglobin caused by beta thalassemia. Fetal hemoglobin has a higher affinity for oxygen, which can help alleviate some symptoms of anemia. The balance between fetal and adult hemoglobin determines the severity of the condition.

There is no known way to prevent HPFH - Beta Thalassemia, as it is a genetic condition. However, genetic counseling can be beneficial for families with a history of the disorder. Prenatal testing and carrier screening can help identify at-risk individuals and inform family planning decisions.

Hereditary Persistence of Fetal Hemoglobin - Beta Thalassemia is a genetic condition that combines features of both HPFH and beta thalassemia. It results in a milder form of anemia due to the continued production of fetal hemoglobin. Diagnosis involves blood tests and genetic analysis, while treatment focuses on symptom management. The prognosis is generally good, with most patients leading normal lives.

If you or a family member has been diagnosed with HPFH - Beta Thalassemia, it's important to understand that this condition is generally mild and manageable. Regular check-ups with your healthcare provider can help monitor your health and address any symptoms. Genetic counseling may be helpful for understanding the condition and its implications for family planning.

1. Craig JE, Barnetson RA, Prior J, Raven JL, Thein SL. Rapid detection of deletions causing delta beta thalassemia and hereditary persistence of fetal hemoglobin by enzymatic amplification. Blood. 1994 Mar 15;83(6):1673-1682.
2. Ottolenghi S, Giglioni B, Taramelli R, et al. Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area? Proc Natl Acad Sci U S A. 1982 Apr;79(7):2347-2351.
3. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci. 1998 Jun 30;850:38-44.
4. Mansoori H, Asad S, Rashid A, Karim F. Delta beta thalassemia: a rare hemoglobin variant. Blood Res. 2016 Sep;51(3):213-214.
5. Khunger JM, Gupta M, Singh R, Kapoor R, Pandey HR. Haematological characterisation and molecular basis of asian Indian inversion deletions delta Beta thalassemia: a case report. J Clin Diagn Res. 2014 Sep;8(9):FD01-2.
6. Verma S, Bhargava M, Mittal S, Gupta R. Homozygous delta-beta Thalassemia in a Child: a Rare Cause of Elevated Fetal Hemoglobin. Iran J Ped Hematol Oncol. 2013;3(1):222-227.
7. Panyasai S, Fucharoen S, Surapot S, Fucharoen G, Sanchaisuriya K. Molecular basis and hematologic characterization of deltabeta-thalassemia and hereditary persistence of fetal hemoglobin in Thailand. Haematologica. 2004 Jul;89(7):777-781.